Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3774961 | 0.81 | CCNE1 (0.48) | BTKLRRK2GRM4TNK2 | |
| SCHEMBL3775083 | 0.80 | AXL (0.46) | AXLLRRK2SYK | |
| SCHEMBL16864468 | 0.78 | LRRK2 (0.37) | LRRK2GRM4 | |
| SCHEMBL3775329 | 0.77 | LRRK2 (0.61) | LRRK2GRM4 | |
| SCHEMBL13060922 | 0.76 | MAPT (0.45) | LRRK2GRM4 | |
| SCHEMBL3775370 | 0.75 | LRRK2 (0.63) | LRRK2GRM4MKNK1 | |
| SCHEMBL3763899 | 0.75 | GRM4 (0.51) | LRRK2GRM4MKNK1 | |
| SCHEMBL3766328 | 0.75 | IGF1R (0.46) | LRRK2 | |
| SCHEMBL3774794 | 0.74 | GRM4 (0.50) | LRRK2GRM4 | |
| SCHEMBL3769241 | 0.74 | CDK2 (0.48) | SYKTNK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AXL 1821/4885BTK 939/4885LRRK2 2309/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | AXL 1893/4885BTK 928/4885LRRK2 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.